Skip to main content
Article thumbnail
Location of Repository

Biological Roles and Therapeutic Potential of Hydroxy-Carboxylic Acid Receptors

By Kashan Ahmed


In the recent past, deorphanization studies have described intermediates of energy metabolism to activate G protein-coupled receptors and to thereby regulate metabolic functions. GPR81, GPR109A, and GPR109B, formerly known as the nicotinic acid receptor family, are encoded by clustered genes and share a high degree of sequence homology. Recently, hydroxy-carboxylic acids were identified as endogenous ligands of GPR81, GPR109A, and GPR109B, and therefore these receptors have been placed into a novel receptor family of hydroxy-carboxylic acid (HCA) receptors. The HCA1 receptor (GPR81) is activated by the glycolytic metabolite 2-hydroxy-propionic acid (lactate), the HCA2 receptor is activated by the ketone body 3-hydroxy-butyric acid, and the HCA3 receptor (GPR109B) is a receptor for the β-oxidation intermediate 3-hydroxy-octanoic acid. While HCA1 and HCA2 receptors are present in most mammalian species, the HCA3 receptor is exclusively found in humans and higher primates. HCA receptors are expressed in adipose tissue and mediate anti-lipolytic effects in adipocytes through Gi-type G protein-dependent inhibition of adenylyl cyclase. HCA2 and HCA3 inhibit lipolysis during conditions of increased β-oxidation such as prolonged fasting, whereas HCA1 mediates the anti-lipolytic effects of insulin in the fed state. As HCA2 is a receptor for the established anti-dyslipidemic drug nicotinic acid, HCA1 and HCA3 also represent promising drug targets and several synthetic ligands for HCA receptors have been developed. In this article, we will summarize the deorphanization and pharmacological characterization of HCA receptors. Moreover, we will discuss recent progress in elucidating the physiological and pathophysiological role to further evaluate the therapeutic potential of the HCA receptor family for the treatment of metabolic disease

Topics: Endocrinology
Publisher: Frontiers Research Foundation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
  2. (2006). 1-Alkylbenzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptorGPR109b.J.Med.Chem.49,
  3. (2008). 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, Gprotein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.
  4. (2007). 3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b.
  5. (2009). 5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.
  6. A.J.,andJayawickreme,C.K.(2006). The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing.
  7. (2001). and International Human Genome Sequencing Consortium
  8. (2001). andmappingof tennovelGproteincoupled receptor genes.
  9. (2006). Antagonismof theprostaglandinD2 receptor 1 suppresses nicotinic acidinduced vasodilation in mice and humans.Proc.Natl.Acad.Sci.U.S.A.
  10. (2009). Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupledreceptor,GPR109B.
  11. (2004). Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a doubleblind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.
  12. (1994). Balance of carbohydrate and lipid utilization during exercise: the “crossover”concept.
  13. (2009). beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.
  14. (2011). Biological roles and therapeutic potential of hydroxy-carboxylic acid receptors.
  15. (2005). Biosynthesis of a Damino acid in peptide linkage by an enzyme from frog skin secretions.
  16. (2000). cDNA representational difference analysis of human neutrophils stimulated by GM-CSF.
  17. (2005). Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G).
  18. (2004). Citricacidcycleintermediatesasligands for orphan G-protein-coupled receptors.
  19. (2006). Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
  20. (2007). Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation inmice.Biochem.Biophys.Res.Commun.
  21. (2009). Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis.
  22. (2007). Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.
  23. (2008). Discoveryofpyrazolopyrimidinesas thefirstclassofallostericagonistsfor thehighaffinitynicotinicacidreceptor GPR109A.
  24. (2000). Drug discovery: a historical perspective.
  25. (2008). Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans.
  26. (2008). Effi-cacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb study.
  27. (1998). Efficacy and safety of an extended-releaseniacin(Niaspan):a long-term study.
  28. (2009). Efficacy and safety of fumaric acid esters in the longterm treatment of psoriasis–a retrospective study (FUTURE).
  29. Elucidation of signaling and functional activities of an orphan GPCR,
  30. (2010). Evidence for constitutive dimerization of niacin receptor subtypes.
  31. (1990). Evidence for lactate production by human adipose tissue in vivo.
  32. (2009). Expression and localization of GPR109A (PUMAG/HM74A) mRNA and protein in mammalian retinal pigment epithelium.
  33. (2009). Extended-release niacin or ezetimibe and carotid intimamediathickness.N.Engl.J.Med.361,
  34. (2009). Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins Other Lipid Mediat.
  35. (2003). Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.
  36. (2005). Free fatty acidsregulategutincretinglucagonlike peptide-1 secretion through GPR120.
  37. (2006). Fuel metabolism in starvation. A n n u .R e v .N u t r .26,
  38. (1990). Fumaric acid therapy for psoriasis: a randomized, double-blind, placebocontrolled study.
  39. Gold,R.(2011).Oraltherapiesformultiple sclerosis: a review of agents in phase III development or recently approved.
  40. (2005). GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
  41. (2009). GPR109A is a G-proteincoupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon.
  42. (2009). GPR109A, GPR109B and GPR81, a family of hydroxycarboxylic acid receptors.
  43. I.,Crampes,F.,Dulac,F.,andRiviere, D.(1999).Lackof antilipolyticeffect of lactate in subcutaneous abdominal adipose tissue during exercise.
  44. (2000). Improved stable isotope dilution-gas chromatography-mass spectrometry method for serum or plasma free 3-hydroxy-fatty acids and its utility for the study of disorders of mitochondrial fatty acid beta-oxidation.
  45. (2011). Inflammation inhibits GPR81 expression in adipose tissue.
  46. (2010). Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3.
  47. (2011). International union of basic and clinical pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B).
  48. (1983). Islet-activating protein prevents nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase inhibition in rat adipocytes.
  49. (1974). Lactate inhibition of lipolysis in exercising man.
  50. (2009). Lactate inhibits lipolysis in fat cells through activation of anorphanG-protein-coupledreceptor,
  51. (1992). Lactate production in adipose tissue: a regulated function with extra-adipose implications.
  52. (2007). Lactate release from adipose tissue and skeletal muscle in vivo: defective insulin regulation in insulin-resistant obese women.
  53. (1994). Lactate release fromthesubcutaneoustissueinlean and obese men.
  54. (2006). Langerhans cells release prostaglandin D2 in response to nicotinic acid.
  55. (1969). Liver and kidney metabolism during prolonged starvation.
  56. (2006). Mediumchain fatty acids as ligands for orphan G protein-coupled receptor GPR84.
  57. (1993). Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors.
  58. (2003). Molecular identification of high and low affinity receptors for nicotinic acid.
  59. (2003). Molecular identification of nicotinic acid receptor.
  60. (2011). Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
  61. (2008). Nicotinic Acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation.
  62. (2007). Nicotinic acid receptor agonists differentially activate downstream effectors.
  63. (2010). Nicotinic acid- and monomethyl fumarateinduced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.
  64. (2006). Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells.
  65. (2008). Nicotinic acid: pharmacological effects and mechanisms of action.
  66. (2011). paper pending published: 19
  67. (2009). Peroxisome proliferatoractivated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81).
  68. (2005). pharmacology. XLVI. G protein-coupled receptor list.
  69. (1962). Plasma free fatty acids during exerciseandtheeffectof lacticacid.Proc.
  70. (2003). PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.
  71. (2001). PUMA-G, an IFN-gammainducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily.
  72. (2003). Pyrazole derivatives as partial agonists for the nicotinic acid receptor.
  73. R.,andBouwesBavinck,J.N.(2003). Long-termsafetyaspectsof systemic therapy with fumaric acid esters in severepsoriasis.
  74. (1996). Regulation of phosphoinositidephospholipasesbyhormones,neurotransmitters,andother agonists linked to G proteins.
  75. (2008). Role of GPR81 in lactatemediatedreductionof adiposelipolysis.
  76. (2010). Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
  77. (2002). Seventransmembrane receptors.
  78. (1998). Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid beta-oxidation disorders.
  79. (2001). Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
  80. (2004). The identification of ligands at orphan G-protein coupled receptors.
  81. (2003). The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.
  82. (2003). The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids.
  83. (2008). The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
  84. (2001). The sequence of the human genome.
  85. (1991). Tolerance to nicotinic acid flushing.
  86. (2005). Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.